Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease

Alzheimer's and Dementia

Volumn 14, Issue 7, 2018, Pages 869-879

  Sutphen, Courtney L ^a   McCue, Lena ^a   Herries, Elizabeth M ^a   Xiong, Chengjie ^a   Ladenson, Jack H ^a   Holtzman, David M ^a   Fagan, Anne M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebrospinal fluid; Longitudinal biomarkers; Neuronal injury

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; NG PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1; NEUROCALCIN; VSNL1 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; COMMUNICATION DISORDER; COMPARATIVE STUDY; ENTORHINAL CORTEX; FEMALE; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SECONDARY PREVENTION; WECHSLER MEMORY SCALE; COGNITION; COGNITIVE DEFECT; LONGITUDINAL STUDY; ONSET AGE;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROCALCIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TAU PROTEINS;

EID: 85044568072     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2018.01.012     Document Type: Article

References (42)

1. Schneider, L.S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 275 (2014), 251–283.
2. Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
3. Perrin, R.J., Fagan, A.M., Holtzman, D.M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 (2009), 916–922.
4. Jack, C.R., Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358.
5. Höglund, K., Kern, S., Zettergren, A., Börjesson-Hansson, A., Zetterberg, H., Skoog, I., et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry, 7, 2017, e995.
6. Mattsson, N., Insel, P.S., Nosheny, R., Tosun, D., Trojanowski, J.Q., Shaw, L.M., et al. Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 71 (2014), 725–734.
7. Fagan, A.M., Xiong, C., Jasielec, M.S., Bateman, R.J., Goate, A.M., Benzinger, T.L.S., et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med, 6, 2014, 226ra30.
8. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
9. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
10. Hellwig, K., Kvartsberg, H., Portelius, E., Andreasson, U., Oberstein, T.J., Lewczuk, P., et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther, 7, 2015, 74.
11. Braunewell, K.H., The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease—old wine in new bottles. Front Mol Neurosci, 5, 2012, 20.
12. Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö M., Santillo, A., Blennow, K., et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol 3 (2015), 12–20.
13. Sutphen, C.L., Jasielec, M.S., Shah, A.R., Macy, E.M., Xiong, C., Vlassenko, A.G., et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72 (2015), 1029–1042.
14. Tarawneh, R., D'Angelo, G., Macy, E., Xiong, C., Carter, D., Cairns, N.J., et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70 (2011), 274–285.
15. Tarawneh, R., Lee, J.-M., Ladenson, J.H., Morris, J.C., Holtzman, D.M., CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78 (2012), 709–719.
16. Kester, M.I., Teunissen, C.E., Sutphen, C., Herries, E.M., Ladenson, J.H., Xiong, C., et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther, 7, 2015, 59.
17. Tarawneh, R., D'Angelo, G., Crimmins, D., Herries, E., Griest, T., Fagan, A.M., et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 73 (2016), 561–571.
18. Laird, N.M., Ware, J.H., Random-effects models for longitudinal data. Biometrics 38 (1982), 963–974.
19. Littell, R.C., Henry, P.R., Ammerman, C.B., Statistical analysis of repeated measures data using SAS procedures. J Anim Sci 76 (1998), 1216–1231.
20. Toledo, J.B., Xie, S.X., Trojanowski, J.Q., Shaw, L.M., Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol (Berl) 126 (2013), 659–670.
21. Palmqvist, S., Mattsson, N., Hansson, O., Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain J Neurol 139 (2016), 1226–1236.
22. Iulita, M.F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 12 (2016), 1132–1148.
23. Watson, J.B., Szijan, I., Coulter, P.M., Localization of RC3 (neurogranin) in rat brain subcellular fractions. Brain Res Mol Brain Res 27 (1994), 323–328.
24. Díez-Guerra, F.J., Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 62 (2010), 597–606.
25. Huang, K.-P., Huang, F.L., Jäger, T., Li, J., Reymann, K.G., Balschun, D., Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 24 (2004), 10660–10669.
26. Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56 (2001), 127–129.
27. Reddy, P.H., Mani, G., Park, B.S., Jacques, J., Murdoch, G., Whetsell, W., et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis 7 (2005), 103–117 discussion 173–180.
28. Wellington, H., Paterson, R.W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N.C., et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 86 (2016), 829–835.
29. Kvartsberg, H., Duits, F.H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 11 (2015), 1180–1190.
30. Kester, M.I., Teunissen, C.E., Crimmins, D.L., Herries, E.M., Ladenson, J.H., Scheltens, P., et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72 (2015), 1275–1280.
31. Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J.Q., et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain J Neurol 138 (2015), 3373–3385.
32. Noor, A., Zahid, S., A review of the role of synaptosomal-associated protein 25 (SNAP-25) in neurological disorders. Int J Neurosci 127 (2017), 805–811.
33. Brinkmalm, A., Brinkmalm, G., Honer, W.G., Frölich, L., Hausner, L., Minthon, L., et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener, 9, 2014, 53.
34. Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R.L., Wiley, C.A., In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation, 7, 2010, 34.
35. Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15 (2016), 673–684.
36. Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85 (2015), 626–633.
37. Gispert, J.D., Monté G.C., Falcon, C., Tucholka, A., Rojas, S., Sánchez-Valle, R., et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 38 (2016), 47–55.
38. Mattsson, N., Insel, P.S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M., et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med 8 (2016), 1184–1196.
39. Zetterberg, H., Review: tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 43 (2017), 194–199.
40. Vos, S.J.B., Gordon, B.A., Su, Y., Visser, P.J., Holtzman, D.M., Morris, J.C., et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44 (2016), 1–8.
41. Beckett, L.A., Harvey, D.J., Gamst, A., Donohue, M., Kornak, J., Zhang, H., et al. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement 6 (2010), 257–264.
42. Lo, R.Y., Hubbard, A.E., Shaw, L.M., Trojanowski, J.Q., Petersen, R.C., Aisen, P.S., et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68 (2011), 1257–1266.